文献速递免疫规划慢病防控与筛查卫生政策与健康促进

BNT162b2疫苗接种与免疫介导共病发病率之间的关联

The association between BNT162b2 vaccinations and incidence of immune-mediated comorbidities.
PubMed 文献 · Vaccine · 2024-05-10

这项基于Clalit健康服务综合数据库的回顾性队列研究比较了接种BNT162b2疫苗与未接种者免疫介导诊断的发生率,并按年龄分组分析。结果显示接种后银屑病、结肠炎、白癜风和风湿性多肌痛风险升高,而SARS-CoV-2感染者纤维肌痛和甲状腺功能减退风险升高。作者认为这些发现应纳入未来疫苗接种规划的风险-获益评估。

要点

  • 接种BNT162b2后所有年龄组银屑病风险升高(HR 1.41-1.69)。
  • 65岁以下接种者结肠炎风险升高(HR 1.38-1.93)。
  • 45-64岁接种者白癜风风险升高(HR 2.82,95%CI 1.57-5.08)。

核心结论

  • BNT162b2疫苗与银屑病、结肠炎和风湿性多肌痛风险升高相关,尽管罕见。
  • 这些发现应作为未来为不同人群规划疫苗接种项目时风险-获益评估的一部分。

研究设计与样本

  • 回顾性队列研究,基于Clalit健康服务(CHS)综合数据库,比较BNT162b2接种者与未接种者免疫介导诊断率。
  • 次要参考队列比较SARS-CoV-2感染者与未感染者。
  • 最短随访期为4个月,队列分为4个年龄组(12-17、18-44、45-64、65岁或以上)。
  • 采用多变量Cox比例风险回归模型,并使用错误发现率(FDR)方法进行多重比较校正。

主要发现

  • 接种BNT162b2后所有年龄组银屑病风险升高(HR 1.41-1.69)。
  • 65岁以下患者结肠炎风险升高(HR 1.38-1.93)。
  • 45-64岁患者白癜风风险升高(HR 2.82,95%CI 1.57-5.08)。
  • 65岁或以上患者风湿性多肌痛风险升高(HR 2.12,95%CI 1.3-3.47)。
  • 参考队列中,18-44岁COVID-19感染者纤维肌痛风险升高(HR 1.72,95%CI 1.36-2.19),45-64岁感染者纤维肌痛风险升高(HR 1.71,95%CI 1.31-2.22),65岁或以上感染者甲状腺功能减退风险升高(HR 1.54,95%CI 1.15-2.07)。

临床怎么用

  • 作者认为这些发现应作为未来为不同人群规划疫苗接种项目时风险-获益评估的一部分。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A large vaccination campaign was initiated worldwide in December 2020 in order to prevent infection with SARS-CoV-2 and severe Covid-19 disease. However, long-term adverse effects of vaccination remain unclear. Therefore, our objective was to examine the association between vaccination and the incidence of autoimmune diagnoses in the first year after vaccine uptake. METHODS: This retrospective cohort study based on Clalit Health Services (CHS) comprehensive database compared the rates of immune-mediated diagnoses among BNT162b2 vaccinated versus unvaccinated individuals. As a reference, a secondary cohort compared individuals infected with Sars-CoV-2 versus uninfected individuals. The minimum follow-up period was 4 months. The cohorts were divided into 4 age groups (12-17, 18-44, 45-64, 65 years or older). Multivariate Cox proportional hazard regression models were applied, followed by a correction for multiple comparisons using the False Discovery Rate (FDR) method, hence accounting for the investigation of multiple clinical outcomes. RESULTS: Increased risk for immune-mediated diagnoses following vaccination with BNT162b2 was observed for psoriasis in all age groups (HR 1.41-1.69), colitis among patients younger than 65 years (HR 1.38-1.93), vitiligo in patients aged 45-64 (HR 2.82, 95 %CI: 1.57-5.08) and for polymyalgia-rheumatica in patients aged 65 years or older (HR 2.12, 95 % CI: 1.3-3.47). In the reference cohort, patients who were infected by Covid-19 were at increased risk for fibromyalgia (HR 1.72, 95 % CI: 1.36-2.19 in individuals aged 18-44; HR 1.71, 95 % CI: 1.31-2.22 in individuals aged 45-64), and hypothyroidism (HR 1.54, 95 % CI: 1.15-2.07 in individuals aged 65 years or older). CONCLUSIONS: The BNT162b2 vaccine was associated with increased risk (though rare) for psoriasis, colitis and polymyalgia rheumatica. These findings should be considered as a part of the risk-benefit assessment when planning future vaccination programs for various population groups.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Shani M, Hermesh I, Feldhamer I, et al. The association between BNT162b2 vaccinations and incidence of immune-mediated comorbidities. Vaccine. 2024. PMID: 38729910. doi:10.1016/j.vaccine.2024.04.097

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。